SUNESIS PHARMACEUTICALS Aktie

2,15 EUR -0,6944%

Zu Ihrem Onlinebroker

kaufen verkaufen

SUNESIS PHARMACEUTICALS Aktienkurs : 08:20 ( 15 Min. verzögert)
2,15 € Letzter Kurs	-0,69% Veränderung	2,16 € Vortag	2,15 € Eröffnungskurs

mehr Informationen

Hoch/Tief		Volumen		Geldkurs	Briefkurs
2,15 - 2,15 Tag	2,45 - 0,803 52 Wochen	0 Tag	322 Ø 52 Wochen	2,15 2.812 Stücke	2,23 2.706 Stücke

SUNESIS PHARMACEUTICALS Aktie…

Wollen Sie wissen, wie es mit dieser Aktie weitergeht?
Wir informieren Sie kostenlos.

Erhalten Sie außerdem Expertenanalysen von:
Gevestor Täglich und John Gossens Daily DAX

26.05.

Biotechnology Stocks To Watch Ahead Of ASCO 2012: Part 3

Sunesis Pharmaceuticals, Inc (SNSS): Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic...
17.05.

5 Stocks Under $10 Poised for Breakouts

Sunesis Pharmaceuticals One more under-$10 stock that's setting up for a breakout trade is Sunesis Pharmaceuticals If you take a look at the chart for Sunesis Pharmaceuticals, you'll notice that this stock has been uptrending strong...

17.05.

Sunesis Pharmaceuticals-Aktie: "sector perform"

Toronto (www.aktiencheck.de) - Jason Kantor, Michael J. Yee, Adnan Butt und Charmaine Chan, Analysten von RBC Capital Markets, stufen die Aktie von SUNESIS PHARMACEUTICALS (ISIN US8673286014 / WKN A1H7V2 ) mit dem Rating "sector perform" ein.
15.05.

Sunesis Pharmaceuticals Jumps On Earnings (PSTI, ACHN, SNSS, AMLN, ZGNX)

Sunesis Pharmaceuticals Inc (NASDAQ:SNSS) went up 9.74% to $2.91. The Company reported first quarter EPS of ($0.30), below the analyst estimate of ($0.18). Revenue for the quarter was $0 versus the c…
15.05.

Sunesis Pharmaceuticals Reports First Quarter 2012 Financial Results and ...

SOUTH SAN FRANCISCO, Calif., May 15, 2012 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today reported financial results for the quarter ended March 31, 2012. Net loss for the three months ended...